This work is licensed under the Creative Commons Attribution 4.0 International License.
Greaves M. Infection, immune responses and the aetiology of childhood leukaemia. Nat Rev Cancer. 2006;6(3):193-203. doi: 10.1038/nrc1816.GreavesMInfection, immune responses and the aetiology of childhood leukaemia20066319320310.1038/nrc1816Open DOISearch in Google Scholar
Icabucci I, Mullighan CG. Genetic basis of acute lymphoblastic leukemia. J Clin Oncol. 2017;35(9):975-83. doi: 10.1200/JCO.2016.70.7836.IcabucciIMullighanCGGenetic basis of acute lymphoblastic leukemia20173599758310.1200/JCO.2016.70.7836Open DOISearch in Google Scholar
Canfield MA, Honein MA, Yuskiv N, Xing J, Mai CT, Collins JS, et al. National estimates and race/ethnic-specific variation of selected birth defects in the United States, 1999-2001. Birth Defects Res A Clin Mol Teratol. 2006;76:747–56. doi: 10.1002/bdra.20294.CanfieldMAHoneinMAYuskivNXingJMaiCTCollinsJSet alNational estimates and race/ethnic-specific variation of selected birth defects in the United States, 1999-20012006767475610.1002/bdra.20294Open DOISearch in Google Scholar
Hasle H, Clemmensen IH, Mikkelsen M. Risks of leukaemia and solid tumours in individuals with Down’s syndrome. Lancet. 2000;355:165–9. doi: 10.1016/S0140-6736(99)05264-2.HasleHClemmensenIHMikkelsenMRisks of leukaemia and solid tumours in individuals with Down’s syndrome2000355165910.1016/S0140-6736(99)05264-2Open DOISearch in Google Scholar
Hasle H, Clemmensen IH, Mikkelsen M. Incidence of cancer in individuals with Down syndrome. Tidsskr Nor Laegeforen. 2000;120:2878–81.HasleHClemmensenIHMikkelsenMIncidence of cancer in individuals with Down syndrome2000120287881Search in Google Scholar
Buitenkamp TD, Izraeli S, Zimmermann M, Forestier E, Heerema NA, van den Heuvel-Eibrink MM, et al. Acute lymphoblastic leukemia in children with Down syndrome: A retrospective analysis from the Ponte di Legno study group. Blood. 2014;123:70–7. doi: 10.1182/blood-2013-06-509463.BuitenkampTDIzraeliSZimmermannMForestierEHeeremaNAvan denHeuvel-Eibrink MMet alAcute lymphoblastic leukemia in children with Down syndrome: A retrospective analysis from the Ponte di Legno study group201412370710.1182/blood-2013-06-509463Open DOISearch in Google Scholar
Harigae H. GATA transcription factors and hematological diseases. Tohoku J Exp Med. 2006;210:1–9. doi: 10.1620/tjem.210.1.HarigaeHGATA transcription factors and hematological diseases20062101910.1620/tjem.210.1Open DOISearch in Google Scholar
Lee P, Bhansali R, Izraeli S, Hijiya N, Crispino JD. The biology, pathogenesis and clinical aspects of acute lymphoblastic leukemia in children with Down syndrome. Leukemia. 2016;30:1816–23. doi: 10.1038/leu.2016.164.LeePBhansaliRIzraeliSHijiyaNCrispinoJDThe biology, pathogenesis and clinical aspects of acute lymphoblastic leukemia in children with Down syndrome20163018162310.1038/leu.2016.164Open DOISearch in Google Scholar
Buitenkamp TD, Pieters R, Gallimore NE, van der Veer A, Meijerink JP, Beverloo HB, et al. Outcome in children with Down’s syndrome and acute lymphoblastic leukemia: role of IKZF1 deletions and CRLF2 aberrations. Leukemia. 2012;26(10):2204-11. doi: 10.1038/leu.2012.84.BuitenkampTDPietersRGallimoreNEvan derVeer AMeijerinkJPBeverlooHBet alOutcome in children with Down’s syndrome and acute lymphoblastic leukemia: role of IKZF1 deletions and CRLF2 aberrations2012261022041110.1038/leu.2012.84Open DOISearch in Google Scholar
Forestier E, Izraeli S, Beverloo B, Haas O, Pession A, Michalová K, et al. Cytogenetic features of acute lymphoblastic and myeloid leukemias in pediatric patients with Down syndrome: an iBFM-SG study. Blood. 2008;111(3):1575-83. doi: 10.1182/blood-2007-09-114231.ForestierEIzraeliSBeverlooBHaasOPessionAMichalováKet alCytogenetic features of acute lymphoblastic and myeloid leukemias in pediatric patients with Down syndrome: an iBFM-SG study2008111315758310.1182/blood-2007-09-114231Open DOISearch in Google Scholar
Maloney KW, Carroll WL, Carroll AJ, Devidas M, Borowitz MJ, Martin PL, et al. Down syndrome childhood acute lymphoblastic leukemia has a unique spectrum of sentinel cytogenetic lesions that influences treatment outcome: a report from the Children’s Oncology Group. Blood. 2010;116(7):1045-50. doi: 10.1182/blood-2009-07-235291.MaloneyKWCarrollWLCarrollAJDevidasMBorowitzMJMartinPLet alDown syndrome childhood acute lymphoblastic leukemia has a unique spectrum of sentinel cytogenetic lesions that influences treatment outcome: a report from the Children’s Oncology Group2010116710455010.1182/blood-2009-07-235291Open DOISearch in Google Scholar
Mullighan CG, Collins-Underwood JR, Phillips LA, Loudin MG, Liu W, Zhang J, et al. Rearrangement of CRLF2 in B-progenitor- and Down syndrome-associated acute lymphoblastic leukemia. Nat Genet. 2009;41(11):1243-46. doi: 10.1038/ng.469.MullighanCGCollins-UnderwoodJRPhillipsLALoudinMGLiuWZhangJet alRearrangement of CRLF2 in B-progenitor- and Down syndrome-associated acute lymphoblastic leukemia2009411112434610.1038/ng.469Open DOISearch in Google Scholar
Lane AA, Chapuy B, Lin CY, Tivey T, Li H, Townsend EC, et al. Triplication of a 21q22 region contributes to B cell transformation through HMGN1 overexpression and loss of histone H3 Lys27 trimethylation. Nat Genet. 2014;46(6):618–23. doi: 10.1038/ng.2949.LaneAAChapuyBLinCYTiveyTLiHTownsendECet alTriplication of a 21q22 region contributes to B cell transformation through HMGN1 overexpression and loss of histone H3 Lys27 trimethylation20144666182310.1038/ng.2949Open DOISearch in Google Scholar
Thompson BJ, Bhansali R, Diebold L, Cook DE, Stolzenburg L, Casagrande AS, et al. DYRK1A controls the transition from proliferation to quiescence during lymphoid development by destabilizing Cyclin D3. J Exp Med. 2015;212(6):953–70. doi: 10.1084/jem.20150002.ThompsonBJBhansaliRDieboldLCookDEStolzenburgLCasagrandeASet alDYRK1A controls the transition from proliferation to quiescence during lymphoid development by destabilizing Cyclin D3201521269537010.1084/jem.20150002Open DOISearch in Google Scholar
Tirado CA, Shabsovich D, Kim Y, et al. A case of B-cell acute lymphoblastic leukemia in a child with Down syndrome bearing a t(2;12)(p12;p13) involving ETV6 and biallelic IGH@ rearrangements. Biomark Res. 2015;3:11. doi: 10.1186/s40364-015-0036-1. eCollection 2015.TiradoCAShabsovichDKimYet alA case of B-cell acute lymphoblastic leukemia in a child with Down syndrome bearing a t(2;12)(p12;p13) involving ETV6 and biallelic IGH@ rearrangements201531110.1186/s40364-015-0036-1. eCollection 2015Open DOISearch in Google Scholar
Hertzberg L, Vendramini E, Ganmore I, Traum P, Pullarkat S, Kallen M, et al. Down syndrome acute lymphoblastic leukemia, a highly heterogeneous disease in which aberrant expression of CRLF2 is associated with mutated JAK2: a report from the International BFM Study Group. Blood. 2010;115(5):1006–17. doi: 10.1182/blood-2009-08-235408.HertzbergLVendraminiEGanmoreITraumPPullarkatSKallenMet alDown syndrome acute lymphoblastic leukemia, a highly heterogeneous disease in which aberrant expression of CRLF2 is associated with mutated JAK2: a report from the International BFM Study Group2010115510061710.1182/blood-2009-08-235408Open DOISearch in Google Scholar
Rampal R, Levine RL. A primer on genomic and epigenomic alterations in the myeloproliferative neoplasms. Bailliere's Best Practice in Clinical Haematology. 2014;27(2):83–93. doi: 10.1016/j.beha.2014.07.001.RampalRLevineRLA primer on genomic and epigenomic alterations in the myeloproliferative neoplasms2014272839310.1016/j.beha.2014.07.001Open DOISearch in Google Scholar
Malinge S, Ben-Abdelali R, Settegrana C, Radford-Weiss I, Debre M, Beldjord K, et al. Novel activating JAK2 mutation in a patient with Down syndrome and B-cell precursor acute lymphoblastic leukemia. Blood. 2007;109(5):2202–4. doi: 10.1182/blood-2006-09-045963.MalingeSBen-AbdelaliRSettegranaCRadford-WeissIDebreMBeldjordKet alNovel activating JAK2 mutation in a patient with Down syndrome and B-cell precursor acute lymphoblastic leukemia200710952202410.1182/blood-2006-09-045963Open DOISearch in Google Scholar
Bercovich D, Ganmore I, Scott LM, Wainreb G, Birger Y, Elimelech A, et al. Mutations of JAK2 in acute lymphoblastic leukaemias associated with Down's syndrome. Lancet. 2008;372(9648):1484–92. doi: 10.1016/S0140-6736(08)61341-0.BercovichDGanmoreIScottLMWainrebGBirgerYElimelechAet alMutations of JAK2 in acute lymphoblastic leukaemias associated with Down's syndrome2008372964814849210.1016/S0140-6736(08)61341-0Open DOISearch in Google Scholar
Gaikwad A, Rye CL, Devidas M, Heerema NA, Carroll AJ, Izraeli S, et al. Prevalence and clinical correlates of JAK2 mutations in Down syndrome acute lymphoblastic leukaemia. Br J Haematol. 2009;144(6):930–2. doi: 10.1111/j.1365-2141.2008.07552.x.GaikwadARyeCLDevidasMHeeremaNACarrollAJIzraeliSet alPrevalence and clinical correlates of JAK2 mutations in Down syndrome acute lymphoblastic leukaemia20091446930210.1111/j.1365-2141.2008.07552.xOpen DOISearch in Google Scholar
Kearney L, Gonzalez De Castro D, Yeung J, Procter J, Horsley SW, Eguchi-Ishimae M, et al. Specific JAK2 mutation (JAK2R683) and multiple gene deletions in Down syndrome acute lymphoblastic leukemia. Blood. 2009;113(3):646–8. doi: 10.1182/blood-2008-08-170928.KearneyLGonzalezDe Castro DYeungJProcterJHorsleySWEguchi-IshimaeMet alSpecific JAK2 mutation (JAK2R683) and multiple gene deletions in Down syndrome acute lymphoblastic leukemia20091133646810.1182/blood-2008-08-170928Open DOISearch in Google Scholar
Haan C, Behrmann I, Haan S. Perspectives for the use of structural information and chemical genetics to develop inhibitors of Janus kinases. J Cell Mol Med. 2010;14(3):504– 27. doi: 10.1111/j.1582-4934.2010.01018.x.HaanCBehrmannIHaanSPerspectives for the use of structural information and chemical genetics to develop inhibitors of Janus kinases2010143504– 2710.1111/j.1582-4934.2010.01018.xOpen DOISearch in Google Scholar
Miettinen M, McCue PA, Sarlomo-Rikala M, Rys J, Czapiewski P, Wazny K, et al. GATA3: a multispecific but potentially useful marker in surgical pathology: a systematic analysis of 2500 epithelial and nonepithelial tumors. Am J Surg Pathol. 2014;38(1):13-22. doi: 10.1097/PAS.0b013e3182a0218f.MiettinenMMcCuePASarlomo-RikalaMRysJCzapiewskiPWaznyKet alGATA3: a multispecific but potentially useful marker in surgical pathology: a systematic analysis of 2500 epithelial and nonepithelial tumors2014381132210.1097/PAS.0b013e3182a0218fOpen DOISearch in Google Scholar
Varsome, The Human Genomics Community; GATA3 c.778+1123T>C SNV | hg38 (varsome.com); GATA3(NM_001002295.2):c.779-1748C>A SNV | hg38 (varsome.com); PIP4K2A c.678+761C>G SNV | hg38 (varsome.com)Search in Google Scholar
Russell LJ, Capasso M, Vater I, Akasaka T, Bernard OA, Calasanz MJ, et al. Deregulated expression of cytokine receptor gene, CRLF2, is involved in lymphoid transformation in B-cell precursor acute lymphoblastic leukemia. Blood. 2009;114(13):2688–98. doi: 10.1182/blood-2009-03-208397.RussellLJCapassoMVaterIAkasakaTBernardOACalasanzMJet alDeregulated expression of cytokine receptor gene, CRLF2, is involved in lymphoid transformation in B-cell precursor acute lymphoblastic leukemia20091141326889810.1182/blood-2009-03-208397Open DOISearch in Google Scholar
Yoda A, Yoda Y, Chiaretti S, Bar-Natan M, Mani K, Rodig SJ, et al. Functional screening identifies CRLF2 in precursor B-cell acute lymphoblastic leukemia. Proc Natl Acad Sci U S A. 2010;107(1):252–7. doi: 10.1073/pnas.0911726107.YodaAYodaYChiarettiSBar-NatanMManiKRodigSJet alFunctional screening identifies CRLF2 in precursor B-cell acute lymphoblastic leukemia20101071252710.1073/pnas.0911726107Open DOISearch in Google Scholar
Adzhubei I, Jordan DM, Sunyaev SR. Predicting functional effect of human missense mutations using PolyPhen-2. Curr Protoc Hum Genet. 2013; Chapter 7:Unit7 20. doi: 10.1002/0471142905.hg0720s76.AdzhubeiIJordanDMSunyaevSRPredicting functional effect of human missense mutations using PolyPhen-22013Chapter 7:Unit7 20.10.1002/0471142905.hg0720s76Open DOISearch in Google Scholar
Schwartzman O, Savino AM, Gombert M, Palmi C, Cario G, Schrappe M, et al. Suppressors and activators of JAK-STAT signaling at diagnosis and relapse of acute lymphoblastic leukemia in Down syndrome. Proc Natl Acad Sci U S A. 2017;114(20):E4030-E4039. doi: 10.1073/pnas.1702489114.SchwartzmanOSavinoAMGombertMPalmiCCarioGSchrappeMet alSuppressors and activators of JAK-STAT signaling at diagnosis and relapse of acute lymphoblastic leukemia in Down syndrome201711420E4030E403910.1073/pnas.1702489114Open DOISearch in Google Scholar
Pieper K, Grimbacher B, Eibel H. B-Cell development and differentiation. J Allergy Clin Immunol. 2013;131(4):959-71. doi: 10.1016/j.jaci.2013.01.046.PieperKGrimbacherBEibelHB-Cell development and differentiation201313149597110.1016/j.jaci.2013.01.046Open DOISearch in Google Scholar
Shah S, Schrader KA, Waanders E, Timms AE, Vijai J, Miething C, et al. A recurrent germline PAX5 mutation confers susceptibility to pre-B cell acute lymphoblastic leukemia. Nat Genet. 2013;45:1226-1231. doi: 10.1038/ng.2754.ShahSSchraderKAWaandersETimmsAEVijaiJMiethingCet alA recurrent germline PAX5 mutation confers susceptibility to pre-B cell acute lymphoblastic leukemia2013451226123110.1038/ng.2754Open DOISearch in Google Scholar
Auer F, Ruschendorf F, Gombert M, Husemann P. Inherited susceptibility to pre B-ALL caused by germline transmission of PAX5 c.547G>A. Leukemia. 2014;28:1136-1138. doi: 10.1038/leu.2013.363.AuerFRuschendorfFGombertMHusemannPInherited susceptibility to pre B-ALL caused by germline transmission of PAX5 c.547G>A2014281136113810.1038/leu.2013.363Open DOISearch in Google Scholar
Winer P, Muskens IS, Walsh KM, Vora A, Moorman AV, Wiemels JL, et al. Germline variants in predisposition genes in children with Down syndrome and acute lymphoblastic leukemia. Blood Adv. 2020;4(4):672-675. doi: 10.1182/bloodadvances.2019001216.WinerPMuskensISWalshKMVoraAMoormanAVWiemelsJLet alGermline variants in predisposition genes in children with Down syndrome and acute lymphoblastic leukemia20204467267510.1182/bloodadvances.2019001216Open DOISearch in Google Scholar
Churchman ML, Qian M, Te Kronnie G, Zhang R, Yang W, Zhang H, et al. Germline genetic IKZF1 variation and predisposition to childhood acute lymphoblastic leukemia. Cancer Cell. 2018;33(5):937-948.e8. doi: 10.1016/j.ccell.2018.03.021.ChurchmanMLQianMTeKronnie GZhangRYangWZhangHet alGermline genetic IKZF1 variation and predisposition to childhood acute lymphoblastic leukemia2018335937948e8.10.1016/j.ccell.2018.03.021Open DOISearch in Google Scholar
Kuehn HS, Boisson B, Cunningham-Rundles C, Reichenbach J. Loss of B Cells in Patients with Heterozygous Mutations in IKAROS. N Engl J Med. 2016;374(11):1032-1043. doi: 10.1056/NEJMoa1512234.KuehnHSBoissonBCunningham-RundlesCReichenbachJLoss of B Cells in Patients with Heterozygous Mutations in IKAROS2016374111032104310.1056/NEJMoa1512234Open DOISearch in Google Scholar
Mullighan, CG, Su X, Zhang J, Radtke I, Phillips LA, Miller CB, et al. Deletion of IKZF1 and prognosis in acute lymphoblastic leukemia. N Engl J Med. 2009;360:470–480. doi: 10.1056/NEJMoa0808253.MullighanCGSuXZhangJRadtkeIPhillipsLAMillerCBet alDeletion of IKZF1 and prognosis in acute lymphoblastic leukemia200936047048010.1056/NEJMoa0808253Open DOISearch in Google Scholar
Mullighan, CG, Goorha S, Radtke I, Miller BC, Coustan-Smith E, Dalton JD, et al. Genome-wide analysis of genetic alterations in acute lymphoblastic leukaemia. Nature. 2007;446:758–764. doi: 10.1038/nature05690.MullighanCGGoorhaSRadtkeIMillerBCCoustan-SmithEDaltonJDet alGenome-wide analysis of genetic alterations in acute lymphoblastic leukaemia200744675876410.1038/nature05690Open DOISearch in Google Scholar
Sherborne AL, Hosking F, Prasad BR, Kumar R, Koehler R, Vijayakrishnan J, et al. Variation in CDKN2A at 9p21.3 influences childhood acute lymphoblastic leukemia risk. Nat Genet. 2010;42(6):492–494. doi: 10.1038/ng.585.SherborneALHoskingFPrasadBRKumarRKoehlerRVijayakrishnanJet alVariation in CDKN2A at 9p21.3 influences childhood acute lymphoblastic leukemia risk201042649249410.1038/ng.585Open DOISearch in Google Scholar
Yoshino H, Nishiyama Y, Kamma H, Chiba T. Functional characterization of a germline ETV6 variant associated with inherited thrombocytopenia, acute lymphoblastic leukemia, and salivary gland carcinoma in childhood. Int J Hematol. 2020;112(2):217-222. doi: 10.1007/s12185-020-02885-y.YoshinoHNishiyamaYKammaHChibaTFunctional characterization of a germline ETV6 variant associated with inherited thrombocytopenia, acute lymphoblastic leukemia, and salivary gland carcinoma in childhood2020112221722210.1007/s12185-020-02885-yOpen DOISearch in Google Scholar
Poggi M, Canault M, Favier M, Turro E. Germline variants in ETV6 underlie reduced platelet formation, platelet dysfunction and increased levels of circulating CD34+ progenitors. Haematologica. 2017;102(2):282-294. doi: 10.3324/haematol.2016.147694.PoggiMCanaultMFavierMTurroEGermline variants in ETV6 underlie reduced platelet formation, platelet dysfunction and increased levels of circulating CD34+ progenitors2017102228229410.3324/haematol.2016.147694Open DOISearch in Google Scholar
Karastaneva A, Nebral K, Schlagenhauf A, Baschin M. Novel phenotypes observed in patients with ETV6-linked leukaemia/familial thrombocytopenia syndrome and a biallelic ARID5B risk allele as leukaemogenic cofactor. J Med Genet. 2020;57(6):427-433. doi: 10.1136/jmedgenet-2019-106339.KarastanevaANebralKSchlagenhaufABaschinMNovel phenotypes observed in patients with ETV6-linked leukaemia/familial thrombocytopenia syndrome and a biallelic ARID5B risk allele as leukaemogenic cofactor202057642743310.1136/jmedgenet-2019-106339Open DOISearch in Google Scholar
Liao W, Liu Y. Treatment outcomes in children with acute lymphoblastic leukemia with versus without coexisting Down's syndrome: A systematic review and meta-analysis. Medicine (Baltimore). 2020;99(29):e21015. doi: 10.1097/MD.0000000000021015.LiaoWLiuYTreatment outcomes in children with acute lymphoblastic leukemia with versus without coexisting Down's syndrome: A systematic review and meta-analysis20209929e2101510.1097/MD.0000000000021015Open DOISearch in Google Scholar
Bohnstedt C, Levinsen M, Rosthøj S, Zeller B, Taskinen M, Hafsteinsdottir S, et al. Physicians compliance during maintenance therapy in children with Down syndrome and acutelymphoblastic leukemia. Leukemia. 2013;27:866–70. doi: 10.1038/leu.2012.325.BohnstedtCLevinsenMRosthøjSZellerBTaskinenMHafsteinsdottirSet alPhysicians compliance during maintenance therapy in children with Down syndrome and acutelymphoblastic leukemia2013278667010.1038/leu.2012.325Open DOISearch in Google Scholar
Buitenkamp TD, Izraeli S, Zimmermann M, Forestier E, Heerema NA, van den Heuvel-Eibrink MM, et al. Acute lymphoblastic leukemia in children with Down syndrome: a retrospective analysis from the Ponte di Legno study group. Blood. 2014;123:70–7. doi: 10.1182/blood-2013-06-509463.BuitenkampTDIzraeliSZimmermannMForestierEHeeremaNAvan denHeuvel-Eibrink MMet alAcute lymphoblastic leukemia in children with Down syndrome: a retrospective analysis from the Ponte di Legno study group201412370710.1182/blood-2013-06-509463Open DOISearch in Google Scholar
Chessells JM, Harrison G, Richards SM, Bailey CC, Hill FG, Gibson BE, et al. Down’s syndrome and acute lymphoblastic leukaemia: clinical features and response to treatment. Arch Dis Child. 2001;85:321–5. doi: 10.1136/adc.85.4.321.ChessellsJMHarrisonGRichardsSMBaileyCCHillFGGibsonBEet alDown’s syndrome and acute lymphoblastic leukaemia: clinical features and response to treatment200185321510.1136/adc.85.4.321Open DOISearch in Google Scholar
Dördelmann M, Schrappe M, Reiter A, Zimmermann M, Graf N, Schott G, et al. Down’s syndrome in childhood acute lymphoblastic leukemia: clinical characteristics and treatment outcome in four consecutive BFM trials. Berlin-Frankfurt- Münster Group. Leukemia. 1998;12:645–51. doi: 10.1038/sj.leu.2400989.DördelmannMSchrappeMReiterAZimmermannMGrafNSchottGet alDown’s syndrome in childhood acute lymphoblastic leukemia: clinical characteristics and treatment outcome in four consecutive BFM trials1998126455110.1038/sj.leu.2400989Open DOISearch in Google Scholar
Matloub Y, Rabin KR, Ji L, Devidas M, Hitzler J, Xu X, et al. Excellent long-term survival of children with Down syndrome and standard-risk ALL: a report from the Children’s Oncology Group. Blood Adv. 2019;3:1647–56. doi: 10.1182/bloodadvances.2019032094.MatloubYRabinKRJiLDevidasMHitzlerJXuXet alExcellent long-term survival of children with Down syndrome and standard-risk ALL: a report from the Children’s Oncology Group2019316475610.1182/bloodadvances.2019032094Open DOISearch in Google Scholar
Whitlock JA, Sather HN, Gaynon P, Robison LL, Wells RJ, Trigg M, et al. Clinical characteristics and outcome of children with Down syndrome and acute lymphoblastic leukemia: a Children’s Cancer Group study. Blood. 2005;106:4043–9. doi: 10.1182/blood-2003-10-3446.WhitlockJASatherHNGaynonPRobisonLLWellsRJTriggMet alClinical characteristics and outcome of children with Down syndrome and acute lymphoblastic leukemia: a Children’s Cancer Group study20051064043910.1182/blood-2003-10-3446Open DOISearch in Google Scholar
Zipursky A. Susceptibility to leukemia and resistance to solid tumors in Down syndrome. Pediatric Research. 2000; 47(6): 704. doi: 10.1203/00006450-200006000-00002.ZipurskyASusceptibility to leukemia and resistance to solid tumors in Down syndrome200047670410.1203/00006450-200006000-00002Open DOISearch in Google Scholar
Chiang JC, Jiang J, Newburger PE, Lawrence JB. Trisomy silencing by XIST normalizes Down syndrome cell pathogenesis demonstrated for hematopoietic defects in vitro. Nat Commun. 2018; 9(1): 5180. doi: 10.1038/s41467-018-07630-y.ChiangJCJiangJNewburgerPELawrenceJBTrisomy silencing by XIST normalizes Down syndrome cell pathogenesis demonstrated for hematopoietic defects in vitro201891518010.1038/s41467-018-07630-yOpen DOISearch in Google Scholar
Laurent AP, Kotecha RS and Malinge S. Gain of chromosome 21 in hematological malignancies: lessons from studying leukemia in children with Down syndrome. Leukemia. 2020;34:1984–1999. doi: 10.1038/s41375-020-0854-5.LaurentAPKotechaRSandMalingeSGain of chromosome 21 in hematological malignancies: lessons from studying leukemia in children with Down syndrome2020341984199910.1038/s41375-020-0854-5Open DOISearch in Google Scholar
Paulsson K, Lilljebjörn H, Biloglav A, Olsson L, Rissler M, Castor A, et al. The genomic landscape of high hyperdiploid childhood acute lymphoblastic leukemia. Nat Genet. 2015;47:672–676. doi: 10.1038/ng.3301.PaulssonKLilljebjörnHBiloglavAOlssonLRisslerMCastorAet alThe genomic landscape of high hyperdiploid childhood acute lymphoblastic leukemia20154767267610.1038/ng.3301Open DOISearch in Google Scholar
Roberts KG. Genetics and prognosis of ALL in children vs adults. Hematology Am Soc Hematol Educ Program. 2018;137–145. doi: 10.1182/asheducation-2018.1.137.RobertsKGGenetics and prognosis of ALL in children vs adults2018137–14510.1182/asheducation-2018.1.137Open DOISearch in Google Scholar
Bolouri H, Farrar JE, Triche T Jr, Ries RE, Lim EL, Alonzo TA, et al. The molecular landscape of pediatric acute myeloid leukemia reveals recurrent structural alterations and age-specific mutational interactions. Nat Med. 2018;24:103–112. doi: 10.1038/nm.4439.BolouriHFarrarJETricheT JrRiesRELimELAlonzoTAet alThe molecular landscape of pediatric acute myeloid leukemia reveals recurrent structural alterations and age-specific mutational interactions20182410311210.1038/nm.4439Open DOISearch in Google Scholar
Nikolaev SI, Garieri M, Santoni F, Falconnet E, Ribaux P, Guipponi M, et al. Frequent cases of RAS-mutated Down syndrome acute lymphoblastic leukaemia lack JAK2 mutations. Nat Commun. 2014;5:4654. doi: 10.1038/ncomms5654.NikolaevSIGarieriMSantoniFFalconnetERibauxPGuipponiMet alFrequent cases of RAS-mutated Down syndrome acute lymphoblastic leukaemia lack JAK2 mutations20145465410.1038/ncomms5654Open DOISearch in Google Scholar
Yoshida K, Toki T, Okuno Y, Kanezaki R, Shiraishi Y, Sato-Otsubo A, et al. The landscape of somatic mutations in Down syndrome-related myeloid disorders. Nat Genet. 2013;45:1293–1299. doi: 10.1038/ng.2759.YoshidaKTokiTOkunoYKanezakiRShiraishiYSato-OtsuboAet alThe landscape of somatic mutations in Down syndrome-related myeloid disorders2013451293129910.1038/ng.2759Open DOISearch in Google Scholar
de Rooij JD, Branstetter C, Ma J, Li Y, Walsh MP, Cheng J, et al. Pediatric non-Down syndrome acute megakaryoblastic leukemia is characterized by distinct genomic subsets with varying outcomes. Nat Genet. 2017;49:451–456. doi: 10.1038/ng.3772.deRooij JDBranstetterCMaJLiYWalshMPChengJetalPediatric non-Down syndrome acute megakaryoblastic leukemia is characterized by distinct genomic subsets with varying outcomes20174945145610.1038/ng.3772Open DOISearch in Google Scholar
Kroll M, Kaupat-Bleckmann K, Mörickel A, Altenl J, Schewel DM, Stanullal M, Zimmermann M, Schrappe M, Cario G. Methotrexate-associated toxicity in children with Down syndrome and acute lymphoblastic leukemia during consolidation therapy with high dose methotrexate according to ALL-BFM treatment regimen. Haematologica. 2020;105(4):1013-1020. doi: 10.3324/haematol.2019.224774.KrollMKaupat-BleckmannKMörickelAAltenlJSchewelDMStanullalMZimmermannMSchrappeMCarioGMethotrexate-associated toxicity in children with Down syndrome and acute lymphoblastic leukemia during consolidation therapy with high dose methotrexate according to ALL-BFM treatment regimen202010541013102010.3324/haematol.2019.224774Open DOISearch in Google Scholar